Oncology treatment outcome in human immunodeficiency virus-positive cancer cervix patients: Where we are and what we achieved?

Autor: Waghmare CM; Department of Radiation Oncology, RMC & PRH, PMTPIMS, Loni, India., Bhanu A; Department of Radiation Oncology, RMC & PRH, PMTPIMS, Loni, India., Dwivedi S; Department of Radiation Oncology, RMC & PRH, PMTPIMS, Loni, India., Pawar HJ; Department of Medical Statistics, PRH, PMTPIMS, Loni, India., Ravichandran M; Department of Radiation Oncology, RMC & PRH, PMTPIMS, Loni, India., Jain VS; Department of Radiation Oncology, RMC & PRH, PMTPIMS, Loni, India.
Jazyk: angličtina
Zdroj: Journal of cancer research and therapeutics [J Cancer Res Ther] 2022 Oct-Dec; Vol. 18 (6), pp. 1537-1540.
DOI: 10.4103/jcrt.JCRT_230_20
Abstrakt: Objective: To find out the epidemiological factors and oncology treatment outcome in human immunodeficiency virus-positive cancer cervix patients (HPCCP).
Materials and Methods: After institutional ethics committee approval, hospital case records of HPCCP registered at the radiation oncology department from January 2011 to December 2018 were retrospectively studied.
Results: The case records of 22 eligible HPCCP were studied. Median age at presentation was 42.5 years. 90.90% of the patients were below 55 years of age. The duration of symptom was <3 months in 63.64% of patients. 68.18% of the patients were FIGO Stage III. Only 11 patients completed the planned treatment. Total target equivalent dose of 2 Gy per fraction delivered was 66 Gy. Seven patients had complete response. Four patients had local recurrence. Median disease-free and overall survival was 27 (14-38) and 18 months (2-48), respectively.
Conclusion: HPCCP present at relatively early age and advanced stage despite short symptom duration. Poor patient compliance and treatment alteration have led to suboptimal outcome.
Competing Interests: None
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje